SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a…

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Figures reflect the source report and its stated period. This article is for information and is not investment advice.



